BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36520345)

  • 21. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma.
    Shen Z; Chen X; Sun C; Lu T; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Zhang X; Wang L; Cai G; Sang W
    Cancer Med; 2023 Dec; 12(23):21138-21147. PubMed ID: 37902266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.
    Pongpruttipan T; Kummalue T; Bedavanija A; Khuhapinant A; Ohshima K; Arakawa F; Niino D; Sukpanichnant S
    Diagn Pathol; 2011 Aug; 6():79. PubMed ID: 21867533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extranodal natural-killer/T-cell lymphoma, nasal type: An immunomorphological study from a regional cancer institute in India.
    Agrawal M; Champaka G; Amirtham U; Jacob LA; Premalata CS
    J Cancer Res Ther; 2022; 18(4):1137-1143. PubMed ID: 36149173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
    Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
    Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.
    Takahashi E; Ohshima K; Kimura H; Hara K; Suzuki R; Kawa K; Eimoto T; Nakamura S;
    Histopathology; 2011 Oct; 59(4):660-71. PubMed ID: 22014047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
    He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
    BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study.
    Wang X; Wen L; Liao J; Feng Y; Li Y; Zhou Z; Zhou C; Huang H
    Br J Haematol; 2023 Aug; 202(4):812-824. PubMed ID: 37394245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement].
    Fréling E; Granel-Brocard F; Serrier C; Ortonne N; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2015 Feb; 142(2):104-11. PubMed ID: 25554664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature.
    Wang X; Gong Z; Li SX; Yan W; Song Y
    BMC Urol; 2017 Sep; 17(1):77. PubMed ID: 28874193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extranodal NK/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56+bright CD16-/+dim NK cells.
    Lima M
    Pathology; 2015 Oct; 47(6):503-14. PubMed ID: 26166665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior.
    Hong M; Lee T; Young Kang S; Kim SJ; Kim W; Ko YH
    Mod Pathol; 2016 May; 29(5):430-43. PubMed ID: 27015135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.
    Montes-Mojarro IA; Chen BJ; Ramirez-Ibarguen AF; Quezada-Fiallos CM; Pérez-Báez WB; Dueñas D; Casavilca-Zambrano S; Ortiz-Mayor M; Rojas-Bilbao E; García-Rivello H; Metrebian MF; Narbaitz M; Barrionuevo C; Lome-Maldonado C; Bonzheim I; Fend F; Steinhilber J; Quintanilla-Martinez L
    Mod Pathol; 2020 May; 33(5):781-791. PubMed ID: 31822801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases.
    Kato S; Asano N; Miyata-Takata T; Takata K; Elsayed AA; Satou A; Takahashi E; Kinoshita T; Nakamura S
    Am J Surg Pathol; 2015 Apr; 39(4):462-71. PubMed ID: 25634749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary extranodal natural Killer/T-cell lymphoma in a child in the colon: A case report.
    Duan Y; Huang J; Haybaeck J; Yang Z
    Medicine (Baltimore); 2021 Jan; 100(3):e24232. PubMed ID: 33546043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review on natural killer/T-cell lymphoma.
    He X; Gao Y; Li Z; Huang H
    Hematol Oncol; 2023 Apr; 41(2):221-229. PubMed ID: 34731509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.